Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 538Neoplasms 393Prostatic Neoplasms 261Colorectal Neoplasms 252Lung Neoplasms 202Carcinoma, Hepatocellular 177Stomach Neoplasms 162Pancreatic Neoplasms 151Rectal Neoplasms 143Motor Activity 128Colonic Neoplasms 126Carcinoma, Non-Small-Cell Lung 118Uterine Cervical Neoplasms 113Polycystic Ovary Syndrome 96Head and Neck Neoplasms 96Esophageal Neoplasms 92Neoplasm Metastasis 71Brain Neoplasms 68Liver Neoplasms 67Ovarian Neoplasms 65Recurrence 60Urinary Bladder Neoplasms 59Pain 55Fatigue 54Lymphoma 53Endometrial Neoplasms 52Anxiety Disorders 50Melanoma 48Thyroid Neoplasms 47Pain, Postoperative 41

Interventions

Leukapheresis 1CF regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Unknown × Plasmacytoma × Clear all
NCT04665076 2020-12-11

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
60 enrolled
Plasma cell

Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡